16 June 2022: Clinical Research
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era
Mevlut Tamer Dincer 1ABCDEF , Zeynep Toker Dincer 2BCE* , Oguz Kagan Bakkaloglu 3CEF , Serkan Feyyaz Yalin 4BE , Sinan Trabulus 1ADE , Aykut Ferhat Celik 3AE , Nurhan Seyahi 1CDE , Mehmet Riza Altiparmak 1ACDEDOI: 10.12659/MSM.936497
Med Sci Monit 2022; 28:e936497
Table 4 Clinical, laboratory, and treatment data of Crohn disease patients with or without renal involvement.
| Crohn’s disease | Patients with renal involvement (n=55) | Control group (n=45) | p |
|---|---|---|---|
| Age in years at diagnosis (mean±SD) | 35.0±11.9 | 35.0±12.1 | 0.970 |
| Follow-up period in years (mean±SD) | 10.7±7.9 | 6.9±4.6 | |
| Ileal | 10 (18.2) | 11 (24.4) | 0.253 |
| Colonic | 4 (7.3) | 5 (11.1) | |
| Ileocolonic | 41 (74.5) | 27 (60.0) | |
| Isolated upper gastrointestinal disease | 0 (0.0) | 2 (4.4) | |
| Perianal disease | 16 (29.1) | 9 (20.0) | |
| Non-stricturing/non-penetrating | 16 (29.1) | 22 (48.9) | 0.128 |
| Stricturing | 17 (30.9) | 10 (22.2) | |
| Penetrating | 22 (40.0) | 13 (28.9) | |
| Active disease | |||
| Endoscopic active | 27 (49.1) | 12 (26.7) | |
| Clinical active (CDAI ≥150) | 31 (56.4) | 18 (40.0) | 0.103 |
| Anti-TNF use | 27 (49.1) | 9 (20.0) | |
| IBD related surgery | 32 (58.2) | 16 (35.6) | |
| Creatinine (mg/dL) | 0.9±0.4 | 0.8±0.2 | |
| e-GFR (mL/min/1.73 m) | 81.7±26.7 | 95.4±19.9 | |
| Uric acid (mg/dL) | 4.6±1.4 | 4.2±1.4 | 0.310 |
| Albumin (g/dL) | 3.8±0.7 | 4.1±0.5 | |
| Hemoglobin (g/dL) | 13.0±4.6 | 13.2±1.8 | 0.063 |
| ESR (mm/h) | 32.1±24.1 | 22.4±20.1 | |
| CRP (mg/L) | 16.5±20.6 | 7.9±13.6 | |
| CDAI – Crohn’s Disease Activity Index; CRP – C-reactive protein; ESR – erythrocyte sedimentation rate; e-GFR – estimated glomerular filtration rate; TNF – tumor necrosis factor. Significant p values are written in bold. | |||